Secukinumab for Ankylosing Spondylitis in Biologic-Free Patients
Treatments studied
Part of Bones, joints & muscles, Skin clinical trials.
This study is looking at how well secukinumab works for people with ankylosing spondylitis in Korea who have never taken a biologic or JAK inhibitor before. It aims to understand if the drug helps control symptoms over a short period of time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of ankylosing spondylitis (a type of inflammatory arthritis).
- Your disease should be active, meaning you have symptoms like back pain, stiffness, or fatigue.
- You must not have used any biologic drugs (like TNF inhibitors or IL-17 inhibitors) or JAK inhibitors before.
- You need to be between 18 and 40 years old.
- Your diagnosis should have been made within the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining two types of immune-blocking drugs (an IL-17 inhibitor and a TNF inhibitor) works better than either alone for treating ankylosing spondylitis. It is for people whose symptoms are not well controlled with NSAIDs.
This trial is testing the safety of a medicine called secukinumab in adults with axial spondyloarthritis (a type of inflammatory arthritis affecting the spine). It may be a good option if you have this condition and want to help researchers learn more about how safe this treatment is for Indian patients.
This study tests a new medication (called 608) for adults with active ankylosing spondylitis (AS). It aims to see if the drug can reduce AS symptoms and improve quality of life.
This trial tests a new oral medication called LNK01001 for adults with active ankylosing spondylitis. It aims to reduce pain, stiffness, and inflammation when standard NSAID treatments no longer help.
This study looks at the bacteria living in your body (the microbiome) in people with ankylosing spondylitis and their close family members. Researchers hope to better understand how these bacteria relate to the disease, which may lead to better treatments in the future.
This trial is for people with ankylosing spondylitis (a type of arthritis that affects the spine) who are otherwise healthy. It may test a treatment to see if it helps control symptoms, whether your disease is active or stable.
Hear when a new Ankylosing Spondylitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.